Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shSIRT5 is a short hairpin RNA (shRNA) construct designed to silence the expression of Sirtuin 5 (SIRT5), an NAD+-dependent deacylase. In the context of acute myeloid leukemia (AML) research, SIRT5 knockdown via shSIRT5 has been shown to increase the succinylation of mitochondrial trifunctional enzyme subunit alpha (HADHA), thereby inhibiting fatty acid oxidation (FAO) and mitochondrial oxidative phosphorylation. This metabolic disruption increases mitochondrial reactive oxygen species (ROS) and sensitizes AML cells to BCL2 inhibitors like venetoclax. The construct is typically delivered via lentiviral transduction for in vitro and in vivo preclinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shSIRT5.